IN THE CLAIMS:

Please amend claims 35, 41-54, and 63 as follows:

26. (Previously Presented) An oligonucleotide or physiologically tolerable salt thereof, comprising a sequence selected from SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 17, SEQ ID NO. 19, and SEQ ID NO. 20.

27. (Previously Presented) An oligonucleotide according to claim 26, wherein the oligonucleotide has one or more modifications.

28. (Previously Presented) The oligonucleotide according to claim 27, wherein the modifications are independently selected from the group consisting of:

a) the replacement of a phosphoric acid diester internucleoside bridge by a modified phospho bridge,

b) the replacement of a phosphoric acid diester internucleoside bridge by a "dephospho" bridge,

c) the replacement of a sugar phosphate unit by another unit,

d) the replacement of a β-D-2'-deoxyribose unit by a modified sugar unit,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

e) the modification or the replacement of a natural nucleoside base by a modified nucleoside base,

f) the conjugation of the oligonucleotide to a molecule which adapts the properties of the oligonucleotide to a specific requirement,

g) the conjugation of the oligonucleotide to a 2'5'-bonded oligoadenylate or a derivative thereof, optionally conjugated via a linker, and

h) the introduction of a 3'-3' or 5'-5' inversion at the 3' or 5' end of the oligonucleotide.

29. (Previously Presented) The oligonucleotide according to claim 28, wherein the oligonucleotide contains one or more modification independently selected from the group consisting of:

a) the replacement of a phosphoric acid diester internucleoside bridge by a modified phospho bridge,

where a modified phospho bridge is a phosphorothioate, phosphorodithioate, $NR^1R^{1'}$-phosphoramidate, boranophosphate, phosphate-(C_1-C_{21})-O-alkyl ester, phosphate-[(C_6-C_{12})aryl-(C_1-C_{21})-O-alkyl] ester, (C_1-C_8)alkylphosphonate, or (C_6-C_{12}) arylphosphonate bridge,

where

R^1 and $R^{1'}$ are independently selected from the group comprising hydrogen, (C_1-C_{18})-alkyl, (C_6-C_{20})-aryl, (C_6-C_{14})-aryl-(C_1-C_8)-alkyl, or

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

R^1 and $R^{1'}$, together with the nitrogen atom carrying them, form a 5- to 6-membered heterocyclic ring which can additionally contain a further heteroatom from the group consisting of O, S, and N;

b) the replacement of a phosphoric acid diester internucleoside bridge by a "dephospho" bridge,

where a "dephospho" bridge is a formacetal, 3'-thioformacetal, methylhydroxylamine, oxime, methylenedimethylhydrazo, dimethylenesulfone, or silyl bridge,

c) the complete or partial replacement of the sugar phosphate backbone (replacement of sugar phosphate units) by other units,

where another unit is suitable for synthesizing a "morpholine derivative" oligomer, a polyamide nucleic acid ("PNA"), or a phosphomonoacid ester nucleic acid,

d) the replacement of a β-D-2'-deoxyribose unit by a modified sugar unit,

where a modified sugar unit is an α-D-2'-deoxyribose, L-2'-deoxyribose, 2'-F-2'-deoxyribose, 2'-O-(C_1-C_6)alkylribose, 2'-O-(C_2-C_6)alkenylribose, 2'-[O-(C_1-C_6)alkyl-O-(C_1-C_6)alkyl]ribose, 2'-NH_2- 2'-deoxyribose, β-D-xylofuranose, α-arabinofuranose, 2,4-dideoxy-β-D-erythro-hexopyranose, a carbocyclic sugar analog, an open-chain sugar analog, or a bicyclo sugar analog,

e) the replacement of a natural nucleoside base by a modified nucleoside base,

where a modified nucleoside base is 5-(hydroxymethyl)uracil, 5 aminouracil, pseudouracil, dihydrouracil, 5-(C_1-C_6-alkyluracil, 5-(C_2-C_6)-alkenyluracil,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER

1300 I Street NW
Washington DC 20005
202 408 4000
Fax 202 408 4400
www.finnegan.com

5-(C_2-C_6)-alkynyluracil, 5-(C_1-C_6)-alkylcytosine, 5-(C_2-C_6)-alkenylcytosine, 5-(C_2-C_6)-alkynylcytosine, 5-fluorouracil, 5-fluorocytosine, 5-chlorouracil, 5-chlorocytosine, 5-bromouracil, 5-bromocytosine, a 7-deaza-7-substituted purine, or a 7-deaza-8-substituted purine,

f) conjugation to a molecule,

where the molecule is a polylysine, intercalator, fluorescent molecule, crosslinker, lipophilic molecule, lipid, steroid, vitamin, polyethylene glycol, oligoethylene glycol, (C_{12}-C_{18})-alkyl phosphate diester, or -O-CH_2-CH(OH)-O-(C_{12}-C_{18})-alkyl group,

g) conjugation to a 2'5'-linked oligoadenylate or a derivative thereof where a 2'5'-linked oligoadenylate or a derivative thereof is a 2'5'-linked triadenylate, 2'5'-linked tetraadenylate, 2'5'-linked pentaadenylate, or cordycepin (2'5'-linked 3'-deoxyadenylate), where the conjugation optionally takes place via a linker and where the 5'-end of the 2'5'-linked oligoadenylate optionally contains a phosphate, diphosphate, or triphosphate group, and

h) the introduction of a 3'-3' or 5'-5' inversion at the 3'- or 5'- end of the oligonucleotide.

30. (Previously Presented) The oligonucleotide according to claim 28, wherein 1 - 5 terminal internucleoside bridges are modified at the 5- or 3'- end of the oligonucleotide.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

31. (Previously Presented) The oligonucleotide according to claim 28, wherein the internucleoside bridges located at the 3'- or 5'- end of nonterminal nucleosides which contain a pyrimidine base are modified.

32. (Previously Presented) The oligonucleotide according to claim 28, comprising a sequence selected from SEQ ID NO. 21, SEQ ID NO. 22, SEQ ID NO. 23, SEQ ID NO. 24, SEQ ID NO. 25, SEQ ID NO. 26, SEQ ID NO. 27, SEQ ID NO. 28, SEQ ID NO. 29, SEQ ID NO. 30, SEQ ID NO. 31, SEQ ID NO. 32, SEQ ID NO. 33, SEQ ID NO. 34, SEQ ID NO. 35, SEQ ID NO. 36, SEQ ID NO. 37, SEQ ID NO. 38, and SEQ ID NO. 39, where "s" in the recited SEQ ID NOs. indicates the position of a modified internucleoside bridge.

33. (Previously Presented) The oligonucleotide according to claim 28, comprising a sequence selected from SEQ ID NO. 40, SEQ ID NO. 41, SEQ ID NO. 42, SEQ ID NO. 43, SEQ ID NO. 44, SEQ ID NO. 45, SEQ ID NO. 46, SEQ ID NO. 47, SEQ ID NO. 48, SEQ ID NO. 49, SEQ ID NO. 50, SEQ ID NO. 51, SEQ ID NO. 52, SEQ ID NO. 53, SEQ ID NO. 54, SEQ ID NO. 55, SEQ ID NO. 56, SEQ ID NO. 57, and SEQ ID NO. 58, where

"x" in the recited SEQ ID NOs., independently of one another, represents a phosphodiester internucleoside bridge or a modified internucleoside bridge, and

"y" in the recited SEQ ID NOs., independently of one another, represents the replacement of a sugar phosphate unit or of a β-D-2'-deoxyribose unit, the modified β-D-2'-deoxyribose unit being located at the 3'- end of "y".

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

34. (Previously Presented) The oligonucleotide according to claim 33, where "y" represents 2' O-methyl-, 2'-O-propyl- or 2'-methoxyethoxyribose, or a PNA unit.

35. (Currently Amended) [[The]] A method for inhibiting the expression of tenascin, said method comprising [[by]] administering an oligonucleotide according to claim [[26]] 32.

41. (Currently Amended) A process for the production of a pharmaceutical comprising mixing an efficacious dose of one or more oligonucleotides according to claim [[26]] 32 with one or more pharmaceutical vehicles and/or additives.

42. (Currently Amended) A process for the preparation of an oligonucleotide according to claim [[26]] 32, said process comprising synthesizing the oligonucleotide on a solid phase.

43. (Currently Amended) A diagnostic comprising one or more oligonucleotides according to claim [[26]] 32.

44. (Currently Amended) A test kit comprising one or more oligonucleotides according to claim [[26]] 32.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

45. (Currently Amended) The oligonucleotide of claim [[26]] 32, wherein the oligonucleotide consists of SEQ ID NO:[[2]] 21.

46. (Currently Amended) The oligonucleotide of claim [[26]] 32, wherein the oligonucleotide consists of SEQ ID NO:[[3]] 22.

47. (Currently Amended) The oligonucleotide of claim [[26]] 32, wherein the oligonucleotide consists of SEQ ID NO:[[4]] 23.

48. (Currently Amended) The oligonucleotide of claim [[26]] 32, wherein the oligonucleotide consists of SEQ ID NO:[[5]] 24.

49. (Currently Amended) The oligonucleotide of claim [[26]] 32, wherein the oligonucleotide consists of SEQ ID NO:[[6]] 25.

50. (Currently Amended) The oligonucleotide of claim [[26]] 32, wherein the oligonucleotide consists of SEQ ID NO:[[7]] 26.

51. (Currently Amended) The oligonucleotide of claim [[26]] 32, wherein the oligonucleotide consists of SEQ ID NO:[[8]] 27.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

52. (Currently Amended) The oligonucleotide of claim [[26]] 32, wherein the oligonucleotide consists of SEQ ID NO:[[9]] 28.

53. (Currently Amended) The oligonucleotide of claim [[26]] 32, wherein the oligonucleotide consists of SEQ ID NO:[[10]] 29.

54. (Currently Amended) The oligonucleotide of claim [[26]] 32, wherein the oligonucleotide consists of SEQ ID NO:[[11]] 30.

55. (Previously Presented) The oligonucleotide of claim 26, wherein the oligonucleotide consists of SEQ ID NO:12.

56. (Previously Presented) The oligonucleotide of claim 26, wherein the oligonucleotide consists of SEQ ID NO:13.

57. (Previously Presented) The oligonucleotide of claim 26, wherein the oligonucleotide consists of SEQ ID NO:14.

58. (Previously Presented) The oligonucleotide of claim 26, wherein the oligonucleotide consists of SEQ ID NO:15.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

59. (Previously Presented) The oligonucleotide of claim 26, wherein the oligonucleotide consists of SEQ ID NO:16.

60. (Previously Presented) The oligonucleotide of claim 26, wherein the oligonucleotide consists of SEQ ID NO:17.

61. (Previously Presented) The oligonucleotide of claim 26, wherein the oligonucleotide consists of SEQ ID NO:19.

62. (Previously Presented) The oligonucleotide of claim 26, wherein the oligonucleotide consists of SEQ ID NO:20.

63. (Currently Amended) An *in vitro* method for inhibiting expression of tenascin by a cell, said method comprising exposing said cell to an oligonucleotide comprising a sequence selected from SEQ ID NO[[. 2]] :21, SEQ ID NO[[. 3]] :22, SEQ ID NO[[. 4]] :23, SEQ ID NO[[. 5]] :24, SEQ ID NO[[. 6]] :25, SEQ ID NO[[. 7]] :26, SEQ ID NO[[. 8]] :27, SEQ ID NO[[. 9]] :28, SEQ ID NO[[. 10]] :29, and SEQ ID NO[[. 11]] :30[[, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 17, SEQ ID NO. 19, and SEQ ID NO. 20]].

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com